Action for Pulmonary Fibrosis research brings hope to IPF patients and their families
- Action for Pulmonary Fibrosis Research Fellow Dr Richard Allen and Trustee Professsor Gisli Jenkins involved in research, funded by Action for Pulmonary Fibrosis, that discovers why some people are more likely to develop IPF than others.
- Research will help understand what causes IPF and the development of more effective treatments.
Action for Pulmonary Fibrosis – the leading pulmonary fibrosis charity in the UK – is delighted to announce their recent research has resulted in a breakthrough for IPF patients and their families.
Researchers, funded by Action for Pulmonary Fibrosis, have discovered parts of the DNA that put some people at higher risk of idiopathic pulmonary fibrosis (IPF).
The research teams compared the DNA of 4,000 people with IPF to 20,000 people without IPF. In total they investigated over 10 million changes in the DNA and found that people with IPF were more likely to have changes in three genes that have not previously been known to be involved with the disease. These genes suggest biological pathways which crucially could be potential targets for new drugs.
One of these genes lies in a pathway that has recently been shown to promote fibrosis in the lungs. There are currently drugs under development that can target this pathway and might benefit patients. The other two genes highlight pathways not previously investigated for IPF but which might drive development of new treatments in the future.
Dr Richard Allen, Action for Pulmonary Fibrosis Research Fellow at the University of Leicester, said: “These are really exciting discoveries and improve our understanding of the disease. Hopefully this research will help in the development of treatments which are desperately needed for this devastating disease.”